Abiomed (NASDAQ: ABMD) is a leading provider of breakthrough medical devices that provide circulatory support. Abiomed is the maker of the world’s smallest heart pump, Impella®. Impella heart pumps are the only Food and Drug Administration-approved line of percutaneous heart pumps indicated for patients with advanced heart failure or cardiogenic shock due to a heart attack. Impella has the unique ability to enable heart recovery, allowing patients to return home with their native hearts.
Abiomed is an excellent resource for news media interested in covering cardiovascular health and heart recovery. Please contact a member of the media team if you would like to connect with a member of our executive team or one of our patients.
Members of the media interested in covering Abiomed or speaking with its executives should contact the media relations team:
Sarah Karr, Communications Manager
Members of the media interested in covering Abiomed financials and earnings news should contact investor relations:
Todd Trapp, Chief Financial Officer
Follow Abiomed on social media and join the online conversation.
Abiomed is active on social media and we invite you to participate in the conversation. Follow us to get updates on company news, read patient stories and learn the latest clinical information about the Impella platform of devices.